Tagitanlimab (HBM-9167) is a humanized monoclonal antibody of the IgG1?? isotype, designed to selectively inhibit the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1. This interaction blockade is pivotal in modulating the immune system's response to tumor cells, potentially enhancing anti-tumor activity. Tagitanlimab is primarily investigated for its therapeutic potential in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), positioning it as a significant candidate for oncology research.
Tagitanlimab (HBM-9167) is a humanized monoclonal antibody of the IgG1?? isotype, designed to selectively inhibit the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1. This interaction blockade is pivotal in modulating the immune system's response to tumor cells, potentially enhancing anti-tumor activity. Tagitanlimab is primarily investigated for its therapeutic potential in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), positioning it as a significant candidate for oncology research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
